Company Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance.
The company’s platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide.
It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical trial for the treatment of essential tremor; Vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain to treat focal onset epilepsy; Relutrigine for the treatment of developmental and epileptic encephalopathies; PRAX-020 to treat KCNT1; and PRAX-050.
In addition, the company develops Elsunersen, a clinical-stage ASO designed to regulate NaV1.2 expression for the treatment of SCN2A-DEE; PRAX-080 that targets PCDH19-related developmental epilepsy; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations.
It has a license agreement with RogCon Inc.; and research collaboration and license agreement with Ionis Pharmaceuticals, Inc. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Oct 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 116 |
| CEO | Marcio De'Souza |
Contact Details
Address: 99 High Street, 30th Floor Boston, Massachusetts 02110 United States | |
| Phone | 617 300 8460 |
| Website | praxismedicines.com |
Stock Details
| Ticker Symbol | PRAX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001689548 |
| CUSIP Number | 74006W108 |
| ISIN Number | US74006W2070 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marcio Silva De'Souza M.B.A. | President, Chief Executive Officer and Director |
| Timothy Edwin Kelly | Chief Financial Officer and Treasurer |
| Alex Nemiroff J.D. | General Counsel and Secretary |
| Dr. Steven Petrou B.Sc. (Hons.), Ph.D. | Co-Founder and Chief Scientific Officer |
| Lauren Mastrocola | Vice President of Finance and Principal Accounting Officer |
| Dr. Karl Hansen Ph.D. | Chief Technical Operations Officer |
| Alex Kane | Vice President of Investor Relations and Corporate Communications |
| Kelly McCue | Chief People Officer |
| Alyssa J. S. Wyant | Chief Regulatory and Quality Officer |
| Megan T. Sniecinski | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 19, 2025 | SCHEDULE 13G | Filing |
| Feb 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 28, 2025 | 10-K | Annual Report |
| Feb 28, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 5, 2025 | SCHEDULE 13G | Filing |